Welcome to our dedicated page for Sigilon Therapeutics news (Ticker: SGTX), a resource for investors and traders seeking the latest updates and insights on Sigilon Therapeutics stock.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) is a biopharmaceutical company based in Cambridge, MA, dedicated to developing functional cures for a wide range of acute and chronic diseases. Utilizing its proprietary Shielded Living Therapeutics™ platform, the company engineers cell-based therapies designed to replace or supplement missing or deficient functions or molecules in patients.
Sigilon's innovative approach involves encapsulating engineered cells in its Afibromer™ biomaterials matrix, which protects them from immune rejection. These cells are then used to produce therapeutic molecules continuously, offering a potentially transformative treatment for diseases such as diabetes. The lead product candidate, SIG-002, aims to treat type 1 diabetes by sensing blood glucose levels and restoring insulin production.
In a significant development, Sigilon Therapeutics recently entered into a definitive agreement with Eli Lilly and Company (NYSE: LLY) for acquisition. This partnership, which has been in collaboration since 2018, focuses on developing encapsulated cell therapies, including SIG-002. Lilly will acquire Sigilon for approximately $34.6 million in cash, along with contingent value rights that could lead to additional payments, potentially totaling $309.6 million.
Rogerio Vivaldi, M.D., CEO of Sigilon, expressed optimism about the merger, emphasizing that Lilly's expertise in diabetes treatment will further advance SIG-002, potentially offering significant benefits to patients. The transaction, expected to close in the third quarter of 2023, will result in Sigilon becoming a wholly-owned subsidiary of Lilly.
Founded by Flagship Pioneering with input from renowned researchers at MIT, Sigilon has made remarkable strides in cell therapeutics. The company's mission is to harness the full power of cell therapy to offer innovative solutions to challenging medical conditions, aiming to improve the quality of life for millions worldwide.
The acquisition by Lilly is expected to enhance Sigilon's research and development capabilities, with both companies focusing on bringing innovative treatments to market. The merger also underscores Sigilon's potential in the biopharmaceutical sector, particularly in the field of diabetes care.
Sigilon Therapeutics (SGTX) reported its Q1 2022 financial results, highlighting a cash position of $103.1 million, expected to fund operations through 2024. The company aims to announce results from preclinical studies of SIG-005 for MPS-1 in the second half of 2022 and plans to submit Clinical Trial Applications in the UK and Brazil. R&D expenses decreased to $11.6 million, while G&A expenses fell to $5.0 million. The net loss narrowed to $13.9 million compared to $19.0 million in Q1 2021, reflecting cost savings from a restructuring initiative.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Needham Healthcare Conference on April 14, 2022, at 8:45 a.m. EDT. The event will be accessible via a webcast on the company's investor website, with a replay available for 90 days. Sigilon focuses on developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, utilizing non-viral engineered cell-based therapies to address conditions like lysosomal diseases and diabetes.
Sigilon Therapeutics (NASDAQ: SGTX) announced a strategic reprioritization to focus on mucopolysaccharidosis type I (MPS-1) and diabetes while optimizing its Shielded Living Therapeutics™ platform. The new leadership team includes a Chief Technical Operations Officer and other promotions. Current cash reserves of $123.4 million are expected to fund operations into 2024. Research and development (R&D) expenses increased to $65.1 million in 2021, up from $53.5 million in 2020. The net loss for 2021 was $77.3 million, compared to $54.6 million in 2020.
Sigilon Therapeutics (NASDAQ: SGTX), a biotechnology company, announced that its President and CEO, Rogerio Vivaldi, M.D., will present at the Barclays Global Healthcare Conference on March 15, 2022, at 10:45 a.m. EDT. The presentation will be followed by a 25-minute Q&A session.
Sigilon focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform, which incorporates engineered cell-based therapies to produce essential therapeutic molecules for conditions like lysosomal diseases and diabetes.
Sigilon Therapeutics (NASDAQ: SGTX) has appointed Dr. Sarah Yuan as Chief Technical Operations Officer, effective March 7, 2022. With over 20 years in biopharmaceuticals, Dr. Yuan previously held leadership roles at 2seventy bio and Sanofi. Her proven experience in manufacturing processes and CMC strategies is expected to enhance the company's Shielded Living Therapeutics™ platform, focusing on chronic diseases like MPS-1 and diabetes. CEO Rogerio Vivaldi expressed optimism about Yuan's immediate impact on achieving key milestones.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) has announced the acceptance of two abstracts, including an oral presentation on MPS-1, for the upcoming 18th Annual WORLD Symposium™ from February 7-11 in San Diego. The oral presentation will detail a novel encapsulated non-viral cell-based therapy for MPS I, scheduled for February 10 at 1:54 PM EST, with a live Q&A session following. A poster on a similar treatment for MPS VI will also be presented on the same day. These advancements highlight Sigilon's commitment to developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) announced a strategic reprioritization focusing on MPS-1 and diabetes while discontinuing other programs. A workforce reduction of approximately 38% will help extend its cash runway into 2024. Following observations of fibrosed spheres in a Phase 1/2 study of SIG-001 for Hemophilia A, further investigations will delay patient dosing for SIG-005 for MPS-1. The firm aims to optimize its Shielded Living Therapeutics™ platform and improve its development pipeline.
Sigilon Therapeutics (NASDAQ:SGTX) reported that fibrosed spheres were identified during a retrieval procedure in a patient from its Phase 1/2 study of SIG-001 for hemophilia A. This trial is currently under FDA clinical hold since July 2021 due to serious adverse events noted in a patient. The company is investigating these findings, which may delay the initiation of its upcoming Phase 1/2 trial of SIG-005 for mucopolysaccharidosis type I. The safety of patients remains a priority, and findings will be reviewed by the Safety Review Committee in December.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) reported significant progress in its clinical programs and leadership appointments in a recent press release. The company is set to complete its investigation into the clinical hold of its Phase 1/2 trial of SIG-001 by year-end. Additionally, it plans to initiate a Phase 1/2 trial for SIG-005 in MPS-1 in Q4 2021. For Q3 2021, net loss widened to $20.2 million, up from $13.2 million in Q3 2020. Cash reserves stood at $140.4 million. The company appointed Dr. May Orfali as Chief Medical Officer, expected to enhance clinical development strategies.
Sigilon Therapeutics (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will participate in a prerecorded fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 a.m. GMT. The chat will be available on-demand and can be accessed via the Company’s website under the Investors & Media section. Sigilon aims to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, utilizing engineered cell-based therapies to provide essential proteins and enzymes for conditions like hemophilia and diabetes.
FAQ
What is the market cap of Sigilon Therapeutics (SGTX)?
What does Sigilon Therapeutics, Inc. do?
What is SIG-002?
Who recently acquired Sigilon Therapeutics?
What is the Shielded Living Therapeutics™ platform?
How much was Sigilon Therapeutics acquired for?
What are the benefits of the acquisition by Eli Lilly?
What are contingent value rights (CVR) in the acquisition deal?
When is the acquisition expected to close?
Who founded Sigilon Therapeutics?
What impact will the acquisition have on Sigilon's operations?
